1.Color-vision abnormalities among patients undergoing tuberculosis treatment
Emerson M. Cruz ; Frances G. Puentespina ; Karlo Paolo L. Alejo ; Evelyn T. Santos-Morabe ; Ma. Lourdes R. Nañ ; agas
Philippine Journal of Ophthalmology 2010;35(1):3-9
Objective:
This study determined the incidence of and risk factors for color-vision
abnormalities among Filipino patients undergoing directly observed treatment
short-course (DOTS) for tuberculosis.
Methods:
A prospective single-cohort study involving newly diagnosed patients with
category-1 tuberculosis, recruited from DOTS health centers in Manila, was
conducted. All patients were given a fixed-dose combination of rifampicin,
isoniazid, ethambutol, and pyrazinamide for 60 days, after which treatment
was continued with rifampicin and isoniazid for 4 more months. The
participants underwent complete eye evaluation including color-vision testing
and were followed up every month up to the conclusion of treatment.
Results:
Out of 93 patients initially enrolled, 64 completed the prescribed follow-up
and constituted the study group. Baseline color vision was normal. After 1 month
of therapy, color vision tested with the Ishihara plates remained normal in all
patients, but one failed the Farnsworth Panel D 15 and was classified as tritan
while 30 (47.88%) failed the Lanthony Desaturated test. The type of abnormality
was unclassified in 20 (66.67 %)patients and tritan in 10 (33.3%). Visual acuity
remained unchanged from baseline. Repeat testing after ethambutol and
pyrazinamide were stopped showed that color vision was normal using the
Ishihara plates and the Farnsworth test, while 5 failed the Lanthony test. Of
these, 3 were unclassified and 2 were tritan. In the 3rd to 6th months follow-up,
no color-vision abnormalities were noted in the 3 tests. The only risk factor
identified was age (p = 0.01) with older patients having a higher risk.
Conclusion
The incidence of color-vision abnormalities among patients undergoing
DOTS was 47.88% using the Lanthony Desaturated test after an average of
39.66 days on quadruple anti-TB therapy. Age was the only significant risk
factor observed. The color-vision abnormalities returned to normal within an
average of 37.85 days after discontinuing ethambutol and pyrazinamide.
Ethambutol
;
Tuberculosis
;
Color Vision